ATAI Life Sciences is a global biotech company builder that leverages a decentralized, technology and data driven platform model to serve millions of people suffering with mental health disorders, including depression, anxiety and addiction.
The company's initial focus is on developing treatments for depression. In early 2020, the company acquired Perception Neuroscience and is developing a ketamine therapy for neuropsychiatric diseases. The company is also the largest investor in COMPASS Pathways, which is developing psilocybin therapies for treatment-resistant depression and has received Breakthrough Therapy status from the FDA.
The company's portfolio of companies and investments also includes:
- Gaba Therapeutics
- Neuronasal Inc.
In addition to its drug development portfolio, the company has invested in Innoplexus and Entheogenix, which deliver big data and AI solutions to big Pharma and biotech companies, as well as provides the technology that it will use to power its in-house drug discovery and development.
Co-Founder & CEO
Matthias Luz, MD
Chief Medical Officer
Srinivas Rao, MD, Ph.D.
Chief Scientific Officer